Finch Therapeutics Group Inc

-2.33 (-13.80%)
Regulatory, Earnings Announcements

Finch Therapeutics Announces Start Of Enrollment In PRISM4 Phase 3 Trial

Published: 11/09/2021 23:42 GMT
Finch Therapeutics Group Inc (FNCH) - Finch Therapeutics Announces Positive Topline Results From Prism-ext Phase 2 Trial of Cp101 for Prevention of Recurrent C. Difficile Infection.
Finch Therapeutics Group - New Data From 132-participant Prism-ext Phase 2 Open-label Trial Show 80.3% Sustained Clinical Cure Rate Through 8 Weeks.
Finch Therapeutics Group Inc - Aggregated 88.2% Sustained Clinical Cure Rate Shown Through 8 Weeks Following Last Dose in Post-hoc Analysis.
Finch Therapeutics Group Inc - Announces Start of Enrollment in Prism4 Phase 3 Trial.
Finch Therapeutics Group Inc - Similar Clinical Cure Rate Maintained Through 24 Weeks and a Safety Profile Consistent With Previously Reported Data.
Revenue is expected to be $5 Million
Adjusted EPS is expected to be -$0.32

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.